Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650286 · ClinicalTrials.gov registry record · Phase 1
Food Study of Modafinil Tablets 200 mg to Provigil® Tablets 200 mg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00650286 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT00650286, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of Mylan modafinil 200 mg tablets to Cephalon Provigil® 200 mg tablets following a single, oral 200 mg (1 x 200 mg) dose administration under fed conditions.
Interventions
- DRUG Modafinil Tablets 200 mg
- DRUG Provigil® Tablets 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2002-09 |
| Est. Completion | 2002-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650286
The ClinicalTrials.gov registry entry for NCT00650286 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Modafinil Tablets 200 mg is the first listed.
NCT00650286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650286 about?
NCT00650286 is a clinical study titled "Food Study of Modafinil Tablets 200 mg to Provigil® Tablets 200 mg". The objective of this study was to investigate the bioequivalence of Mylan modafinil 200 mg tablets to Cephalon Provigil® 200 mg tablets following a single, oral 200 mg (1 x 200 mg) dose administration under fed conditions.
What is the current status of trial NCT00650286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2002-09. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00650286?
The interventions under investigation include: Modafinil Tablets 200 mg (DRUG), Provigil® Tablets 200 mg (DRUG).
Who is sponsoring clinical trial NCT00650286?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.